Is the Weight-Loss Drug Revolution Causing a Frailty Epidemic? - Kanebridge News
Share Button

Is the Weight-Loss Drug Revolution Causing a Frailty Epidemic?

As millions flock to GLP-1s, doctors warn the drugs can cause rapid and significant muscle loss.

By Natasha Dangoor
Mon, May 18, 2026 10:24amGrey Clock 5 min

Chanel Robinson achieved exactly what the gold rush of blockbuster weight-loss drugs promised: She lost nearly 100 pounds, lowered her cholesterol to normal levels and reined in her polycystic ovary syndrome.

Yet, nearly three years into her journey on Mounjaro, the 30-year-old from Atlanta, Ga., is discovering the hidden costs of the slimmed-down life.

Robinson experiences muscle fatigue daily, feeling physically weak, frail and often cold. Robinson said she experiences bursts of sluggishness sporadically during the day, and has trouble with basic tasks like opening a jar. “It shouldn’t be this difficult,” she said.

GLP-1 drugs like Ozempic, Mounjaro and Zepbound have been a success for public health and the pharmaceutical companies that make them. Obesity rates are falling, the volume of food consumed in America is declining and retailers report a slump in sales of plus-size apparel. It has improved health and happiness for millions of people.

But for at least some of the 13 million Americans taking them, losing muscle along with fat is an unexpected downside that isn’t broadly discussed or immediately apparent.

The drugs can cause rapid and significant loss of lean muscle mass, up to 10%, comparable to a decade or more of aging, according to an analysis published by the American Diabetes Association.

The loss of lean tissue is similar to weight loss from dieting, but the magnitude over a short period can lead to frailty, instability and lack of coordination, doctors and researchers say. Another concern is that losing muscle could slow down patients’ metabolism, leading to weight regain.

“We are curing obesity by encouraging frailty,” said Daniel Green, principal research fellow at the University of Western Australia, who contributed to the analysis. Many taking weight-loss medications initially lose fat and feel great, but quickly start to feel weak and lethargic, he said.

Green’s research showed that the rate of muscle loss could be slowed significantly by regular strength workouts. “It should say ‘must be taken with resistance training’ on the box,” he said.

Drugmakers say weight-loss drugs should be taken only on the advice of a physician and as part of a long-term plan that includes diet and exercise.

A spokesperson for Eli Lilly, maker of Zepbound, said Food and Drug Administration guidelines say it should be used “with increased physical activity.” The spokesperson added: “Sustainable weight loss is about more than a number on a scale.”

Both Eli Lilly and Novo Nordisk said clinical trials showed users did lose some lean muscle tissue, though at far lower rates than fat. Liz Skrbkova, a spokeswoman for Novo Nordisk, said that trials for its drug Wegovy showed changes in muscle mass didn’t “significantly differ” from patients who took a placebo. Eli Lilly said users lost three times more fat weight than lean tissue.

Rayna Kingston, 30, from Denver, said her injections of Zepbound left her feeling so tired the following day that she struggled to complete anything other than basic tasks. She said she shifted her dose to a Sunday because Mondays were her least busy day. Her partner would bring her meals in bed because she felt so weak.

She stopped exercising, and said her doctor didn’t give her any guidance on strength training or muscle maintenance. “I was relying on Reddit forums to understand what was happening to my body,” she said. She got so frustrated with the fatigue she came off the medication just under two months later.

Experts say that losing muscle at such a rate can be especially dangerous for those over 50 or with osteoporosis or limited mobility as it could lead to an increased risk of injury. “Loss of muscle mass is detrimental to moving around and quality of life, but it is also not safe,” said Katsu Funai, associate professor at the University of Utah.

Elderly Americans are set to be able to get GLP-1s from Medicare from July.

There is also pushback from doctors and regulators against using weight-loss drugs as a “quick fix” to lose a bit of weight.

People who take GLP-1s regain weight four times faster than those who lose weight through lifestyle interventions, and weight regained is often mostly fat, according to a recent analysis published in the British Medical Journal. There currently are few, if any, guidelines or studies on de-prescribing the drugs, researchers say.

The nurse practitioner who prescribed Robinson the medication didn’t warn her that resistance training is essential to maintaining muscle mass, Robinson said. She said she regrets not exercising and now does Pilates once a week.

In the haste to disrupt the obesity epidemic, weight loss has been treated as the singular, undisputed metric of success, which experts say is problematic.

“People worship body weight as an outcome measure because it’s simple, quick and inexpensive,” said Green. “But what matters is fat and muscle mass, which is more expensive to measure as it requires an MRI.”

Grace Parkin, 34, a property manager from Sheffield, England, has lost 125 pounds after she started taking Mounjaro in 2024. “I don’t care about my muscle mass as long as I’m a healthy weight,” she said.

The doctor who prescribed the drug didn’t tell her to exercise, though the pharmacy that sold the medication gave her information on exercise and protein intake, she said.

She didn’t exercise and said she soon felt side effects: a “deathly cold, from the inside” likely because of the drug. Still, she vowed to keep going, saying the weight loss was worth it.

In response to some of the side effects, drug companies are hoping to develop weight-loss treatments aimed at preserving or even building lean muscle mass.

German drugmaker Boehringer Ingelheim recently said it had promising results from one such drug. Eli Lilly last September halted a trial of a similar drug.

While weight-loss medications are designed as lifelong treatments for chronic diseases, namely obesity and Type 2 diabetes, they are increasingly marketed as lifestyle fixes.

Tennis superstar Serena Williams, who used GLP-1s to slim down after having children, was featured in this year’s Super Bowl commercial promoting telehealth company Ro’s weight-loss medication.

Serena Williams holding a GLP-1 weight-loss medicine injector.

Serena Williams poses for an ad campaign for a weight-loss drug. Ro/Handout/Reuters

Women may be particularly vulnerable to the drugs’s side effects, which can also include nausea, diarrhea, migraines and rarer cases of pancreatitis.

A study last year from a university hospital in Turin, Italy, showed that women are more prone to adverse reactions to weight-loss drugs than men, including muscle loss.

Green, the researcher, said the issue is of particular concern to those taking GLP-1s recreationally and who don’t have much muscle mass to begin with. Others say a lack of oversight is compounding the issue.

“Patients are self-reporting, and telehealth companies don’t have the patient in front of them to conduct a proper medical assessment,” said Rupal Mathur, an internist in Houston whose practice specializes in weight loss.

She said medical spas are prescribing off-label drugs that don’t meet the criteria set out by the FDA that justify a prescription.

The number of people taking weight-loss drugs who are not living with obesity or Type 2 diabetes is difficult to track since it is unregulated.

However, an analysis by the FDA from 2023 found that more than half of new Ozempic and Mounjaro users didn’t have Type 2 diabetes.

Scientists are calling for more clinical trials to pin down the full effects of weight-loss drugs on muscle loss in different demographics.

“The only studies that have been done have looked at people living with obesity or Type 2 diabetes,” said Green. “That makes it all the more concerning for those using weight-loss drugs in an ad hoc or unregistered way.”

MOST POPULAR

The Australian leather house has opened an immersive four-day pop-up in Manhattan, unveiling its Bloom Collection and redefining what a product launch can look like.

Following the successful launch of its Palais Collection, MAISON de SABRÉ has unveiled a new modular handbag system offering more than 720 styling combinations.

Related Stories
Lifestyle
The Global Economy Looks Vulnerable to an AI Bust
By Jason Doughlas 12/11/2026
Lifestyle
The Parents Suing Schools Because Their Kids Got Bad Grades
By Zusha Elinson 10/11/2026
Lifestyle
How to Leave Your Career While Keeping the Door Open to a Comeback
By Callum Borchers 05/11/2026

The global economy is increasingly exposed to the risks of an AI slowdown, as data-centre investment fuels growth, trade and technology exports worldwide. While Asian economies benefit from booming chip and hardware demand, a pullback in AI spending could trigger market losses, weaken global trade and increase recession risks.

By Jason Doughlas
Thu, Nov 12, 2026 4 min

A message from the violent swings in stock markets over the past week: The fallout from an artificial-intelligence bust wouldn’t stop at the U.S.’s shores.

The AI build-out has been an engine of growth not just for the U.S. this year but for the whole global economy. Squeezed by the energy crunch caused by the Iran war, the world has relied heavily on U.S. data-center investment to power otherwise lackluster growth.

Global trade has thrived as Asian economies such as China, Taiwan and South Korea have enjoyed booming exports of computer chips, server racks and electronic equipment to feed ravenous demand for computing power in the U.S.

The Silicon Valley bounty is spreading as other economies join the party. Assembly hubs such as Vietnam and Mexico are seeing exports take off. Malaysia, Thailand and Australia are building data centers of their own. Europe’s industrial giants are supplying the power and cooling systems that make the AI revolution possible.

Yet the anxiety that spread through global markets in the aftermath of the U.S. midterm elections shows this growing dependency on Silicon Valley has a downside.

A slowdown in AI investment would punish exports in economies that in many cases show few other signs of growth. A sustained stock slide would crush mom-and-pop investors all over the world who have piled into technology stocks in anticipation of bumper returns. Overstretched budgets mean governments have limited room to respond with more spending.

Economists calculating what might happen if the pace of investment slows or the AI boom turns to full-blown bust say the only real question is how severe the global consequences will be.

“There is very little that can be done to prevent a global recession should the AI boom collapse,” said Frederic Neumann, chief Asia economist at HSBC in Hong Kong.

Stock markets have been on a wild ride since the Democrats’ victory in the U.S. midterm elections sparked concerns that Congress will hit the brakes on data-center development.

The latest upset in the industry has been the alleged spying scandal engulfing Nvidia, the linchpin of the AI ecosystem because of its deep pockets and advanced chips.

Stocks have clawed back some losses in recent days, moves that suggest many investors think the selloff is overdone. Even so, key stocks and indexes remain well below recent peaks. The tech-heavy Nasdaq index closed Wednesday 8% below its year-to-date high. Japan’s Nikkei index is down 16%, and South Korea’s Kospi, home to major memory-chip maker Samsung Electronics and SK Hynix, is down 43%.

For now, the stock-market gyrations haven’t spilled over into real economic activity, with global data pointing to the AI boom still going strong.

Jensen Huang, CEO of NVIDIA, gives a keynote address on stage in front of screens displaying partner company logos.
Jensen Huang is under scrutiny after an affair with an alleged spy. Sean Gallup/Getty Images

Asian economies are still seeing bumper export growth, with many of the gains driven by surging prices for chips and other hardware. China’s exports were up 35% year-over-year in October, according to figures from data provider CEIC. South Korea’s were up 93%, with Japan, Taiwan, Singapore and others also posting double-digit gains.

Economists at Capital Economics said the export bonanza means global trade is on track for its best spell of annual growth this year since the days of hyperglobalization in the early 1990s, excluding the big rebounds after Covid-19 and the 2008-09 financial crisis.

But the consulting firm warned that as much as 80% of recent export growth has been concentrated in AI-related goods, leaving global trade vulnerable to any change in U.S. spending on data centers. China, South Korea and other major economies are beset by weak consumption, meaning a drop-off in trade would have an outsize hit on growth.

Political and regulatory hurdles could drag on data-center investment. So, too, could rising interest rates or disappointments on earnings if AI firms’ revenues fail to keep up with outlays. The AI splurge already eclipses past infrastructure booms such as the railroads, and even without external pressure it might struggle to maintain that breakneck rate of growth.

As data-center investment slows, “AI capex will turn from a major prop to a drag on world trade,” Marcel Thieliant, head of Asia-Pacific at Capital Economics, said in a report.

Some economists have looked back to the dot-com bubble of the early 2000s as a yardstick to measure the possible costs to the global economy of an AI blowup.

In that episode, U.S. business investment sank and stocks crashed, hurting U.S. consumer spending and crushing imports.

Activists hold signs reading "Stop Data Centers" and "Off Fossil Fuels" during a protest.
Data centers were an issue in the U.S. midterm elections. Michael Nigro/Pacific Press/ZUMA Press

As a share of gross domestic product, U.S. imports of IT-related equipment fell 55% in two years from their mid-2000 peak, according to Oxford Economics—a drop that hit Asian and other economies that were suppliers of the goods. Global trade plummeted, and world growth in 2001 collapsed to just 2%, consistent with a global recession.

The globalized financing of the AI boom would in a bust spread financial pain around the world, adding to the damage from a steep fall in trade. Gaurav Ganguly, head of international economics at Moody’s Analytics in London, said the world would struggle to absorb a sharp AI stock slide on top of an oil shock, tariffs and rising interest rates.

“The result could be a severe economic shock with global recessionary consequences,” he said.